Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9716627 | 1.00 | FOLH1 (0.58) | FOLH1CPB2SLC6A5GSRSLC15A2 | |
| SCHEMBL9716590 | 0.95 | FOLH1 (0.51) | FOLH1CPB2SLC6A5SLC15A2GNPAT | |
| SCHEMBL9716595 | 0.95 | FOLH1 (0.51) | FOLH1CPB2SLC6A5SLC15A2GNPAT | |
| SCHEMBL9716599 | 0.95 | FOLH1 (0.51) | FOLH1CPB2SLC6A5SLC15A2GNPAT | |
| SCHEMBL4080076 | 0.88 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRSLC15A2 | |
| SCHEMBL4075195 | 0.88 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRSLC15A2 | |
| SCHEMBL30357164 | 0.88 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRSLC15A2 | |
| SCHEMBL1711242 | 0.88 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRSLC15A2 | |
| SCHEMBL16692902 | 0.88 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRSLC15A2 | |
| SCHEMBL30357165 | 0.88 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRSLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746865-A1 | NOVEL AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND REJUVENATING SKIN AND EXTENDING LONGEVITY | Sytheon Ltd. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260041620-A1 | NOVEL AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND IMPROVING SKIN REJUVENATION AND LONGEVITY | SYTHEON LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250099355-A1 | AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND IMPROVING SKIN REJUVENATION AND LONGEVITY | SYTHEON LTD (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025019570-A1 | NOVEL AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND REJUVENATING SKIN AND EXTENDING LONGEVITY | SYTHEON LTD. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC | 2008-06-19 | — | — | US | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | F2, SERPINC1, PLAT | FOLH1 1993/4885CPB2 282/4885SLC6A5 2903/4885 |
| US-20250099355-A1 | AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND IMPROVING SKIN REJUVENATION AND LONGEVITY | AADAT, BCAT2, BCAT1 | FOLH1 2743/4885CPB2 2996/4885SLC6A5 168/4885 |
| US-20260041620-A1 | NOVEL AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND IMPROVING SKIN REJUVENATION AND LONGEVITY | TYR, ARG2, BCAT2 | FOLH1 2225/4885CPB2 3152/4885SLC6A5 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.